Add Yahoo as a preferred source to see more of our stories on Google. Dr. Deephak Swaminath and his team at Medical Center Hospital were the first in West Texas to use the Pulse Select PFA (pulsed ...

Pulse Biosciences (NASDAQ:PLSE) said it is sharpening its focus on its nanosecond pulsed field ablation platform for atrial ...

A novel pulsed field ablation technology was safe and prevented atrial arrhythmia recurrence in most patients with paroxysmal ...

CellFX marks another route for Afib ablation technology ...

Dr. Deephak Swaminath and his team at Medical Center Hospital were the first in West Texas to use the Pulse Select PFA (pulsed field ablation) system. Pulse Select PFA is an emerging and newer, ...

Treatment success with pulsed field ablation was higher at 1 year than with antiarrhythmic drug therapy for patients with persistent atrial fibrillation.

HAYWARD, Calif.--(BUSINESS WIRE)-- Pulse Biosciences, Inc. (PLSE), a company leveraging its novel nPulse™ technology using its proprietary Nanosecond Pulsed Field Ablation™ (nanosecond PFA or nsPFA™) ...

In patients with persistent atrial fibrillation, those receiving pulsed field ablation as first-line therapy had less risk ...

HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc. (Nasdaq: PLSE), a company leveraging its novel and proprietary CellFX® Nanosecond Pulsed Field Ablation™ (nsPFA™) technology, today announced ...

Company’s proprietary system used to treat initial five patients in first-in-human feasibility study for patients with atrial fibrillation HAYWARD, Calif.--(BUSINESS WIRE)--Pulse Biosciences, Inc.

There are both clinical and economic implications, as payers have been discouraging ablation in this population, one expert ...